[1] Bauskin AR, Brown DA, Junankar S, et al. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome[J]. Cancer Res, 2005, 65(6):2330-2336.
[2] Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers[J]. Clin Cancer Res, 2004, 10(7):2386-2392.
[3] Shnaper S, Desbaillets I, Brown DA, et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome[J]. Int J Cancer, 2009, 125(11):2624-2630.
[4] Zhao L, Lee BY, Brown DA, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling[J]. Cancer Res, 2009, 69(19):7696-7703.
[5] Zhang L, Yang X, Pan HY, et al. Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma[J]. Oral Oncol, 2009, 45(7):627-632.
[6] Xue H, Lü B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach[J]. J Proteome Res, 2010, 9(1):545-555.
[7] Wallin U, Glimelius B, Jirstrom K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer[J]. Br J Cancer, 2011, 104(10):1619-1627.
[8] Staff AC, Trovik J, Eriksson AG, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer[J]. Clin Cancer Res, 2011, 17(14):4825-4833.
[9] Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis[J]. Clin Cancer Res, 2006, 12(1):89-96.
[10] Baek SJ, Kim KS, Nixon JB, et al. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities[J]. Mol Pharmacol, 2001, 59(4):901-908.
[11] Albertoni M, Shaw PH, Nozaki M, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1[J]. Oncogene, 2002, 21(27):4212-4219.
[12] Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1[J]. Nat Med, 2007, 13(11):1333-1340.
[13] Kim KK, Lee JJ, Yang Y, et al. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells[J]. Carcinogenesis, 2008, 29(4):704-712.
[14] Boyle GM, Pedley J, Martyn AC, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity[J]. J Invest Dermatol, 2009, 129(2):383-391.
[15] Senapati S, Rachagani S, Chaudhary K, et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway[J]. Oncogene, 2010, 29(9):1293-1302.
[16] Wakchoure S, Swain TM, Hentunen TA, et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss[J]. Prostate, 2009, 69(6):652-661.
[17] Whiteside MA, Chen DT, Desmond RA, et al. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance[J]. Oncogene, 2004, 23(3):744-752.
[18] Huang CY, Beer TM, Higano CS, et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15[J]. Clin Cancer Res, 2007, 13(19):5825-5833.
[19] Proutski I, Stevenson L, Allen WL, et al. Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells[J]. Mol Cancer Ther, 2009, 8(9):2566-2574.
[20] Akiyama M, Okano K, Fukada Y, et al. Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts[J]. FEBS Lett, 2009, 583(5):933-937.
[21] Ago T, Kuroda J, Pain J, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes[J]. Circ Res, 2010, 106(7):1253-1264.
[22] Tan M, Wang Y, Guan K, et al. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway[J]. Proc Natl Acad Sci U S A, 2000, 97(1):109-114.
[23] Baek SJ, Kim JS, Moore SM, et al. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein[J]. Mol Pharmacol, 2005, 67(2):356-364.
[24] Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells[J]. J Biol Chem, 2005, 280(19):18636-18642.
[25] Wollmann W, Goodman ML, Bhat-Nakshatri P, et al. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells[J]. Carcinogenesis, 2005, 26(5):900-907.
[26] Krieg AJ, Rankin EB, Chan D, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth[J]. Mol Cell Biol, 2010, 30(1):344-353.
[27] Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system[J]. Cancer Res, 2003, 63(15):4648-4655.
[28] Chen SJ, Karan D, Johansson SL, et al. Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells[J]. Prostate, 2007, 67(5):557-571. |